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A B S T R A C T
Background
Chemotherapy is the treatment of choice in patients with advanced or metastatic colorectal cancer (CRC) where surgical resection of
metastases is not an option. Both irinotecan (IRI) and fluoropyrimidines are often included in first- or second- line chemotherapy
treatment regimens in such patients. However, it is not clear whether combining these agents is superior to irinotecan alone.
Objectives
To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with
fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings.
Search methods
We searched the following electronic databases to identify randomized controlled trials: Cochrane Colorectal Cancer Group Specialised
Register (January 13, 2016), Cochrane Central Register of Controlled Trials (CENTRAL)(The Cochrane Library Issue 12, 2016),
Ovid MEDLINE (1950 to January 13, 2016), Ovid EMBASE (1974 to January 13, 2016), registers of controlled trials in progress,
references cited in relevant publications and conference proceedings in related fields (BioMed Central and Medscape’s Conference).
The key authors or investigators of all eligible studies, and professionals in the field were contacted when necessary. The search from
January 2016 identified one eligible study, an ongoing trial currently presented as an abstract, to be considered in an update of this
review.
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Selection criteria
Randomized controlled trials (RCTs) investigating the efficacy and safety of IRI chemotherapy combined with fluoropyrimidine
compared with IRI alone for the treatment of patients with advanced CRC, regardless of treatment line settings.
Data collection and analysis
Study eligibility and methodological quality were assessed independently by the two authors, and any disagreement was solved by a
third author. The data collected from the studies were reviewed qualitatively and quantitatively using the Cochrane Collaboration
statistical software RevMan 5.3.
Main results
Five studies were included in this review with a total of 1,726 patients. The top-up search resulted in an additional ongoing trial,
the results of which have not been incorporated in this review. Among five included studies, no reduction in all-cause mortality was
observed in the combination arm, with a summary hazard ratio (HR) of 0.91 (95% CI: 0.81-1.02). Longer progression-free survival
was observed in those treated with the combination chemotherapy (HR: 0.68, 95% CI: 0.53-0.87), however, this result may have been
driven by findings from the single first-line treatment setting study.
The quality of evidence for overall survival was low and for progression-free survival was moderate, mainly due to study limitation from
the lack of information on randomisation methods and allocation concealment.
There were higher risks of toxicity outcomes grade 3 or 4 diarrhoea and grade 1 or 2 alopecia, and a lower risk of grade 3 or 4 neutropenia
in controls compared to the invervention group. Evidence for toxicity has been assessed to be low to moderate quality.
Authors’ conclusions
There was no overall survival benefit of the irinotecan and fluoropyrimidine treatment over irinotecan alone, thus both regimens remain
reasonable options in treating patients with advanced or metastatic CRC. Given the low and moderate quality of the evidence, future
studies with sufficient numbers of patients in each treatment arms are needed to clarify the benefit observed in progression-free survival
with combination irinotecan and fluoropyrimidines.
P L A I N L A N G U A G E S U M M A R Y
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free
survival in patients with advanced and/or metastatic colorectal cancer
Background:
Patients with inoperable colorectal cancer (CRC) are likely to receive chemotherapy drugs as their primary treatment. Irinotecan (IRI)
and fluoropyrimidines are two such drugs widely used in this setting, either alone or as part of multi-drug chemotherapy treatments.
Objectives:
Currently, there is lack of evidence comparing the combination of IRI and fluoropyrimidine with IRI alone. Therefore it was the aim
of this review to compare the two treatments for patients with inoperable advanced or metastatic CRC.
Investigation and study characteristics:
We searched the literature on January 13, 2016. We identified five randomised controlled trials with a total of 1,726 patients comparing
the combination of IRI and fluoropyrimidine with IRI alone. The search in January 2016 resulted in an additional ongoing trial, the
results of which have not been incorporated in this review.
This review compared IRI and fluoropyrimidine with IRI alone in terms of overall survival, progression-free survival, toxicity, response
rates and quality of life.
Main results:
There is no evidence to suggest any superiority of the combination of IRI and fluoropyrimidine over IRI alone, but our results on overall
survival are limited by the number of studies available to date. Longer progression-free survival was seen from adding fluoropyrimidines
to IRI. Based on current evidence, both the combination regimens and IRI alone seem equally effective for treating advanced or
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metastatic patients. Patients in the intervention arm were less likely to develop grade 3 or 4 diarrhea and grade 1 or 2 alopecia, and
more likely to have grade 3 or 4 neutropenia, compared to patients receiving IRI alone.
Quality of the evidence:
There was moderate quality evidence from these studies suggesting longer progression-free survival from adding fluoropyrimidines to
IRI. However, findings need to be confirmed by larger, high-quality randomised clinical trials.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
IRI with fluoropyrimidines versus single agent IRI for advanced and/or metastatic colorectal cancer
Patient or population: patients with advanced and/or metastatic colorectal cancer
Settings: first- and second- line treatments
Intervention: IRI with fluoropyrimidines
Control: Single agent IRI.
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213 per 1000 140 per 1000
(109 to 181)
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49 per 1000 16 per 1000
(3 to 77)
Moderate
33 per 1000 11 per 1000
(2 to 52)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; HR: Hazard ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open-label intervention)
and one level for imprecision (Lack of sufficient number of samples may have reduced the statistical power of the analysis)
2 Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open-label intervention)
3 Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open-label intervention)
4 Downgraded one level for study limitations (Allocation concealment was only clear for one of the five studies, open-label intervention)


















































































































































































B A C K G R O U N D
Description of the condition
Colorectal cancer (CRC) is currently the third most commonly di-
agnosed cancer for men and the second most common for women,
as well as a leading cause of death worldwide (Ferlay 2010). In
the United States, it was estimated that 136,830 people (71,830
men and 65,000 women) were diagnosed with CRC and 50,310
died from the disease in 2014 (Siegel 2014). Despite the higher
incidence and mortality rates of CRC in more developed countries
, these rates have been decreasing over the last two decades, partic-
ularly in the United States (Jemal 2011; Siegel 2013). Conversely,
both CRC incidence and mortality have increased in less devel-
oped countries, largely owing to limited resources and inadequate
healthcare infrastructure (Center 2009).
Early stage CRC is potentially curable by surgery (Kuhry 2008).
However, 20-25% of CRC patients are first diagnosed with
metastatic disease, where curative surgical resection is unlikely to
be carried out (Siegel 2014; Van Cutsem 2014), and many pa-
tients relapse with metastatic disease after potentially curative re-
sections. For these patients systemic chemotherapy is often the
treatment of choice, with the objectives of relieving symptoms,
increasing survival and improving quality of life (Simmonds 2000;
Ragnhammar 2001).
Description of the intervention
Antimetabolite fluoropyrimidines have been the backbone of CRC
chemotherapy for the past 40 years. For decades, treatment effi-
cacy from fluorouracil (FU) monotherapy has been limited. The
subsequent combination of 5-fluorouracil (5-FU) with leucovorin
(LV), a reduced folate that increases thymidylate synthetase in-
hibition, was used to modulate effects of 5-FU and improve its
efficacy (ACCMAP 1992). This combination has resulted in bet-
ter response rates than 5-FU alone for advanced CRC (Thirion
2004) and remains the main component of most chemotherapy
regimens in CRC, either as an intravenous (IV) bolus injection,
infusion, or both (Chau 2005; Maiello 2005).
Irinotecan is a semisynthetic derivative of the natural alkaloid
camptothecin which inhibits topoisomerase I, thus impeding
DNA uncoiling and leading to double-stranded DNA breaks
(Hsiang 1985). This drug was shown to have antitumour activity
against CRC when administered intravenously alone in a first-line
setting, or as a second-line regimen for patients with advanced
CRC that is refractory to FU (Conti 1996; Pitot 1997; Rothenberg
1999; Rougier 1997; Rougier 1998)
In more recent years, a number of oral fluoropyrimidines such
as capecitabine have become available. In addition to its more
convenient use as an oral agent, capecitabine has been shown in
clinical trials to have superior safety profiles compared to IV 5-FU/
LV with similar (non-inferior) overall survival (OS), progression-
free survival (PFS) and time to progression (TTP) for patients
with metastatic CRC (Petrelli 2012; Van Cutsem 2004). These
encouraging results suggest that oral fluoropyrimidine agents may
serve as a suitable alternative to IV agents for CRC chemotherapy
treatment. However, when both treatment arms were combined
with irinotecan (IRI), IV 5-FU/LV regimens demonstrated longer
PFS and less toxicity in metastatic CRC compared to capecitabine
(Montagnani 2010), and the combination of capecitabine and IRI
is used less commonly now.
How the intervention might work
As a first-line chemotherapeutic regimen for CRC, IV IRI alone
was demonstrated to have comparable antitumour activity to 5-
FU/LV (Cao 2000, Saltz 2000). Besides a different mechanism
of action from 5-FU, the lack of cross-resistance of IRI to previ-
ous 5-FU/LV treatment, as shown by its similar activity against
untreated and 5-FU-pretreated CRC, is the rationale for com-
bining it with fluoropyrimidines as first-line therapy for this dis-
ease (Rougier 1997). The synergistic effects between IRI and flu-
oropyrimidines have been suggested to be comparable with that
of IRI and oxaliplatin despite difference different toxicity profiles
(Colucci 2005; Tournigand 2004). As the second-line treatment
for advanced CRC, two phase III studies have shown modest ben-
efits in survival with IRI of 2.3 months and 2.7 months compared
to IV 5-FU and best supportive care, respectively (Rougier 1998;
Cunningham 1998). Until now, the superiority of IRI combined
with fluoropyrimidines over fluoropyrimidines alone has been as-
sumed and the combination regimen is now widely used for ad-
vanced CRC patients in clinical practice (Douillard 2000; Maiello
2000; Folprecht 2008; Giessen 2011; Muro 2010).
Why it is important to do this review
Several randomized controlled trials (RCTs) comparing IRI in
combination with fluoropyrimidines against IRI alone suggested
that the combination regimen leads to better outcomes in OS
and TTP for advanced CRC (Saltz 2000; Seymour 2007), while
the results of another trial and a meta-analysis indicated that IRI
monotherapy had equivalent efficacy and toxicity (Clarke 2011;
Graeven 2007). However, the meta-analysis comparing IRI and IV
5-FU/LV combination regimen (FOLFIRI) for second-line treat-
ment of CRC was not specific for trials concurrently including
both treatment arms (Clarke 2011). Thus the benefit of IRI and
fluoropyrimidines over IRI monotherapy remains unclear. Tak-
ing their efficacy and toxicity into account, we therefore under-
took this study to systematically compare the combination regi-
men with IRI alone to determine which regimen is more suitable
for advanced CRC patients, either as a first-line or a second-line
therapy.
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O B J E C T I V E S
The aim of this systematic review was to compare the efficacy and
safety of two chemotherapeutic regimens, IRI monotherapy or
IRI in combination with fluoropyrimidines, for patients with ad-
vanced CRC when administered in the first or second-line setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) investigating the efficacy and
safety of chemotherapeutic regimens that compared IRI combined
with fluoropyrimidine against IRI alone for the treatment of pa-
tients with advanced CRC, regardless of treatment line settings,
were eligible for the inclusion. If trials enrolled more than two
groups, we only extracted data that related to the two regimens.
Relevant cluster RCTs were eligible for this review.
Types of participants
Studies involving patients diagnosed histologically or cytologically
with locally advanced and/or metastatic CRC were included.
Types of interventions
The experimental group received the combination regimen,
namely IRI with fluoropyrimidines administered intravenously or
orally; the control group received single agent IRI. Other agents
were acceptable as long as they were common to both treatment
arms, except LV, which is specific to IV 5-FU.
Types of outcome measures
Primary outcomes
The primary outcome measures were:
• Overall survival (OS),
• Time to progression (TTP) or progression-free survival
(PFS)
All outcomes were analysed on an intention to treat (ITT) basis.
Studies which reported survival outcomes either directly or by
curves were included, if the relevant data could be obtained by
using Parmar methods (Parmar 1998; Tierney 2007).
Secondary outcomes
The secondary outcome measures were:
• toxicity, classified according to the National Cancer
Institute Common Toxicity Criteria (NCI-CTC version 2.0),
• response rates, classified according to the RECIST criteria
(see below),
• quality of life, measured by the European Organisation for
Research and Treatment of Cancer quality of life questionnaire
(EORTC QLQ-C30)
Response rates were classified according to Response Evaluation
Criteria In Solid Tumors (RECIST version 1.0) (Therasse 2000),
where measurable target and non-target lesions were determined
at baseline and evaluated during follow up. A complete response
(CR) was defined as disappearance of full lesion, while partial
response (PR) referred to a decrease of at least 30% of lesion and
progressive disease (PD) an increase of at least 20% of the lesion.
Those with insufficient changes to be categorized as either PR or
PD were classified as stable disease (SD). CR and PR were used as
outcomes in this review.
Search methods for identification of studies
We performed an updated search in January 2016, resulting in
identification of an ongoing trial added to ‘Studies awaiting clas-
sification’.
Electronic searches
Published or unpublished trials eligible for inclusion were identi-
fied by performing searches in the following databases:
• Cochrane Colorectal Cancer Group Specialized Register
(December 2014);
• Cochrane Central Register of Controlled Trials
(CENTRAL)(The Cochrane Library Issue 12, 2014) (Appendix
1);
• Ovid MEDLINE from 1950 to 8 December 2014
(Appendix 2)
• Ovid EMBASE from 1974 to 8 December 2014 (Appendix
3)
• Science Citation Index from 1900 to 8 December 2014
(Appendix 4)
In each database, both medical subject headings and free-text
searching were performed in order to improve the sensitivity of the
searches. All above databases were searched from the beginning of
electronic records to the time at which the search was conducted
and eligible studies in both English and non-English languages
were identified without any publication date or publication status
limitations.
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Searching other resources
Published meta-analyses and relevant reviews, registers of con-
trolled trials in progress (World Health Organization’s Interna-
tional Clinical Trials Registry and ClinicalTrials.gov), references
cited in relevant publications and conference proceedings in re-
lated fields were also searched (BioMed Central and Medscape’s
Conference). The key authors or investigators of all eligible stud-
ies, and professionals in the field were contacted if necessary in
order to obtain other relevant information on the topic. In addi-
tion, bibliographies of identified trials and relevant references were
hand-searched.
Data collection and analysis
Selection of studies
The title, abstract and keywords of every record from retrieved
studies obtained by applying the above search strategies were
checked independently against the inclusion criteria by two re-
viewers (AW and NY). All eligible studies were included irrespec-
tive of whether measured outcome data were reported on. Dis-
agreements were resolved by a third reviewer (WW). Potentially
eligible trials were retrieved in full for further assessment. Where
more than one publication of a single trial existed, only the pub-
lication with the most complete data was included unless the rel-
evant outcomes were only published in earlier versions.
Data extraction and management
Data was extracted from published papers independently by two
reviewers (WW and NY). Any disagreement was resolved by a
third reviewer (MVH). Data for overall survival and progression-
free survival was extracted from the publications or estimated from
survival curves where necessary. The following data of each study
was requested: response rates (complete and partial), toxicity, the
outcomes of quality life measurements, if any, the schedule and
dosing of IRI or fluoropyrimidines, and baseline characteristics
including age, sex, performance status, site of metastatic disease,
whether or not patients had received previous adjuvant chemo-
therapy, site of primary tumor (rectum versus colon). If a study
did not include one of the comparators of interest, only available
results on the other interventions were included. The investiga-
tors of included studies were asked to supply updated data where
possible.
Assessment of risk of bias in included studies
The methodological quality of the included studies was evalu-
ated independently by two reviewers (WW and AW) with dis-
agreements resolved by a third reviewer (MVH) according to the
Cochrane Handbook. For each study, the following domains were
assessed (Higgins 2011):
1. Selection bias: the generation of allocation schedule (truly
random, quasi random, systematic) & concealment of treatment
allocation.
2. Performance bias: blinding of study participants and
personnel.
3. Detection bias: blinding of outcome assessors.
4. Attrition bias: completeness of follow-up, withdrawal and
drop-out rates and whether analyses were performed by ITT.
5. Selective outcome reporting: evidence that outcome data
have been reported based on the nature of the results.
6. Other biases, such as deviation from the study protocol in a
way that does not reflect clinical practice.
The methods and procedures within each domain were judged as
low, high or unclear risk of bias based on criteria specified in the
Cochrane Risk of Bias tool (see Appendix 5)(Higgins 2011). Any
disagreements were resolved by discussion between the reviewers.
Investigators were contacted where this information could not be
extracted from the publication.
Measures of treatment effect
The absolute effects of treatment at different time points were ob-
tained from publication data or read from simple (non-stratified)
Kaplan Meier curves of included trials. Median survivals and TTP
(or PFS) were also estimated from Kaplan-Meier curves.
The information on survival and progress from each study was
summarised as a log hazard ratio (HR). When HRs were not re-
ported, observed (O) and the log-rank expected (E) number of
events and variance (V) were calculated from the numbers of events
and the numbers at risk at each time interval in published Kaplan-
Meier survival curves (Parmar 1998; Tierney 2007). These num-
bers were used to estimate the HRs for all time intervals. When
estimates from Cox regression were reported, the HRs were in-
cluded in the analysis instead of those manually derived from the
log-rank method (O-E/V). The general inverse variance method
was used to obtain summary log HRs from combined studies.
All time to event analyses were performed by ITT.
Unit of analysis issues
For individual trials, the unit of analysis used was individual pa-
tients. For any eligible cluster RCTs, meta-analysis was conducted
based on results from analysis that took into account clustering de-
sign. For studies in which control of clustering was not performed
or reported, and individual patient data was not available, the in-
tervention effects of cluster RCT were corrected by reducing the
size of each trial to its ’effective sample size’, which is the number
of original sample size divided by the ’design effect’. The design
effect were calculated as 1 + (M-1)* ICC, where M is the aver-
age cluster size and ICC is the intracluster correlation coefficient
(Higgins 2011b).
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Dealing with missing data
All principal investigators of the selected trials were contacted and
asked to provide data that were missing or information which
could not be extracted from the publication. Among five authors
contacted, two immediately complied, another two no longer had
any data at hand, one did not respond. Fortunately, most of the
authors whose additional information was unavailable have pro-
vided detailed survival data on their published papers.
Assessment of heterogeneity
The studies were evaluated clinically and methodologically to as-
sess if it was reasonable to consider combining data. Statistical
heterogeneity was measured by the visual inspection of the for-
est plots and statistically through an assessment of homogeneity
based on the Chi2 test for which a p-value of less than 0.10 was
considered an indication of substantial heterogeneity. The I2 mea-
surement was calculated as an indicator of the amount of statisti-
cal variation not attributable to sampling error. A value of more
than 50% was considered to represent substantial heterogeneity.
Where necessary, further investigations were undertaken to deter-
mine the source of the observed heterogeneity and in particular,
whether there were any outlying studies driving this heterogeneity.
Analyses were then conducted both with and without the outlying
studies as part of a sensitivity analysis.
Assessment of reporting biases
Funnel plots were visually inspected to assess publication bias. The
presence of publication bias was indicated by an asymmetrical dis-
tribution of data points derived from HR estimates and standard
errors of log HRs from individual studies in relation to the pooled
estimate effect.
Data synthesis
The statistical package Review Manager 5.3 (RevMan 5.3) pro-
vided by the Cochrane Collaboration was used for analysing data.
For primary outcomes, pooled results on overall survival or pro-
gression-free survival were expressed as HRs with 95% confidence
intervals (CI) by calculating the overall HRs and its variance across
the trials. A random effects model was used to address potential
statistical heterogeneity among included studies. All time-to-event
analyses were performed by ITT.
For secondary outcomes, data on toxicity, response rates and qual-
ity of life, where available, were analysed as dichotomous data and
the outcomes were reported as relative risks (RRs) with 95% CI.
A Mantel-Haenszel test was employed to obtain pooled estimates
across studies under a random effects model.
Subgroup analysis and investigation of heterogeneity
Where different routes of administration were used, studies were
grouped according to whether fluoropyrimidines were adminis-
tered orally or intravenously. A second subgroup analysis was per-
formed according to the different settings (first- or second-line)
under which individual trials were categorised. We also explored
possible interactions between different methods of administration
of 5-FU in combination with IRI (infusion versus bolus) in order
to investigate possible sources of heterogeneity. The Chi2 test for
interaction was used to test for consistency of effects across these
subsets of trials.
Sensitivity analysis
Sensitivity analyses were performed in order to assess the ro-
bustness of our results to heterogeneity, different assumptions or
methodological approaches:
1. Removing studies at a high risk of bias in all domains
assessed using the Cochrane Risk of Bias Tool
2. Exclusion of studies that used other agents (in both study
arms) that may affect treatment effects of study regimen.
Summary of findings
We evaluated the quality of evidence of the two primary outcomes
(Overall survival and Progression-free survival), and one secondary
outcome (Toxicity) using the Grading of Recommendations As-
sessment, Development and Evaluation (GRADE) approach and
presented it in ’Summary of Findings’ tables.
The GRADE system classifies the quality of evidence in one of
four grades:
1. High: Further research is very unlikely to change our
confidence in the estimate of effect;
2. Moderate: Further research is likely to have an impact on
our confidence in the estimate of effect and may change the
estimate;
3. Low: Further research is very likely to have an important
impact on our confidence on the estimate og effect and is likely
to change the estimate; or
4. Very low: Any estimate of effect is very uncertain.
The quality of evidence were to be downgraded by one (serious
concern) or two levels (very serious concern) for the following
reasons: risk of bias, inconsistency (unexplained heterogeneity, in-
consistency of results), indirectness (indirect population, interven-
tion, control, outcomes) and imprecision (wide confidence inter-
vald, single trial). The quality could also be upgraded by one level
due to large summary effect.
R E S U L T S
Description of studies
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Results of the search
We identified a total of 3,117 records through the electronic
searches. After removing duplicates, a total of 2,006 records were
left to be checked for eligibility, of which 1,997 studies were clearly
irrelevant and thus excluded. The updated search in January 2016
resulted in one ongoing trial, which has been added to ‘Studies
awaiting classification’ (Bendell 2014). We retrieved full text of
the remaining 8 records for further assessment (Bécouarn 2001;
Clarke 2011; Graeven 2007; Saltz 2000; Seymour 2007; Fiorentini
2012; Mitchell 2011; Popov 2006). We excluded 3 studies for
reasons listed in the Characteristics of excluded studies. In total, 5
RCTs fulfilled the inclusion criteria (Bécouarn 2001, Clarke 2011,
Graeven 2007,Saltz 2000, Seymour 2007). All included studies
were individual trials and no relevant cluster RCTs were identified.
The study flow diagram is shown in Figure 1.
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Figure 1. Study flow diagram
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Included studies
Five studies were included in this review, and details on IRI and
fluoropyrimidine regimens are presented in Table 1. A total of
1,726 patients were randomised: 686 in the IRI-fluoropyrimidine
combination group and 1,040 in the control group. Four of the
studies administered IRI and the combination of IRI with fluo-
ropyrimidine as a second-line treatment (Bécouarn 2001; Clarke
2011; Graeven 2007; Seymour 2007) and one study as a first-line
treatment (Saltz 2000); all used 5-FU IV as the fluoropyrimidine
of choice in the combination arm. No additional chemotherapeu-
tic agents apart from LV in the 5-FU arm were used except in
Bécouarn 2001, where oxaliplatin was administered in both treat-
ment arms in addition to IRI and 5FU/LV. Seymour 2007 com-
pared three strategies of sequential chemotherapy, where a second-
line treatment with IRI was administered in the control group and
the IRI and 5-FU combination was used as a second-line treatment
in one of the intervention groups, both groups had previously been
treated with 5-FU as the first-line drug of choice. Randomisation
occurred prior to first-line treatments and therefore, the numbers
of patients actually assigned to the combination IRI + 5-FU and
IRI groups (185 and 356 patients, respectively) were lower than
those at randomisation (365 and 710 patients, respectively). All
randomised patients were included when combining results from
time-to-event analyses. One study (Saltz 2000) administered three
treatment arms: IRI alone, 5-FU/LV alone, and a combination of
IRI and 5-FU-LV, but a comparison was only made between the
latter two. ITT analyses were conducted in all studies.
Excluded studies
Among the remaining three studies from the search, two trials did
not have randomized allocations of IRI regimens and thus were
excluded (Mitchell 2011; Popov 2006). One study was excluded
because it used intra-arterial administration of IRI-loaded drug-
eluting beads (DEBIRI) instead of an IV or oral route (Fiorentini
2012).
Risk of bias in included studies
Risk of bias was assessed from the available information reported
by the authors and summarised in the Characteristics of included
studies section. This assessment is also presented as the risk of bias
graph (Figure 2) and risk of bias summary (Figure 3). Randomisa-
tion technique was one of the main components of the assessment.
All studies randomised their patients when allocating treatments.
Except for Seymour 2007, randomisation took place prior to treat-
ment with experimental and control regimens. Further details on
risk of bias in included studies are as following.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The methods used for randomisation and allocation concealment
were less explicit. Only two RCTs described the technique used for
randomization, minimisation (Clarke 2011; Seymour 2007). Al-
location concealment was only clear for one study (Clarke 2011),
which conducted central randomisation by telephone, resulting
in 20% of the studies to have shown low risk of selection bias
based on allocation concealment and 40% based on randomisa-
tion methods (Figure 2).
Blinding
One trial was open label and therefore judged to have had high risk
of bias (Saltz 2000). Blinding of personnel or study participants
was not reported in any of other included studies. No mention
of blinding of outcome assessors was made in any publication.
Hence, 20% of all studies had high risk of bias from the lack of
blinding (Figure 2).
Incomplete outcome data
A total of 15 patients withdrew from the studies Bécouarn 2001;
Clarke 2011; Graeven 2007; Saltz 2000: 8 in the experimental
group, 7 in the control group, and 2 had no mention of their allo-
cated group. In Seymour 2007, 154 patients who failed first-line
treatment with 5-FU did not receive the allocated combination of
IRI + fluoropyrimidines and 302 did not receive allocated IRI as
second-line treatment. Except for two patients withdrawing from
the study in Graeven 2007 and one patient that refused the use
of their data after withdrawing from the study in Clarke 2011,
all patients were included in the analysis. No reason was reported
for patient withdrawal in the Graeven 2007 study, hence we re-
garded this study to have unclear risk of attrition bias, Overall,
this showed 80% of included trials to have low risk of attrition
bias (Figure 2).
Selective reporting
Limited information on pre-specified outcomes was found when
assessing reporting bias in individual studies, however, most stud-
ies reported both significant and insignificant findings in their
publications. Figure 4 shows the funnel plot for results on OS.
From visual inspection, all data points representing the estimates
and precision of individual studies fell within the triangle com-
prising 95% confidence interval of the pooled effect estimate, with
larger and more precise studies occupying the top of the inverted
funnel and smaller and less precise studies more diversely scattered
at the bottom. Most smaller and less precise studies (Bécouarn
2001; Graeven 2007) reported positive results. Although an assy-
metrical funnel plot was shown, interpretation is hampered given
the small number of studies. Therefore, more studies are needed
to determine a true reporting bias.
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Figure 4. Funnel plot for comparisons of overall survival
Other potential sources of bias
No other potential sources of bias were identified from the studies
and thus we assessed all studies (100%) to have low risk of other
bias.
Effects of interventions
See: Summary of findings for the main comparison IRI with
fluoropyrimidines versus single agent IRI for advanced and/or
metastatic colorectal cancer
1. Primary outcomes
The primary outcomes of this review were Overall Survival (OS)
and Progression-free Survival (PFS)
1.1 Overall survival
As seen in Table 1, median OS ranged between 9.5-15.4 months
in the intervention arms across all studies, and between 10.7-13.9
months in the control arms. When comparing efficacy, subgroup
analyses was performed according to the line of treatment, al-
though only one study was found for the first-line treatment set-
ting (Saltz 2000). For OS, analysis of both subgroups combined
failed to show any statistically significant difference in overall mor-
tality risk between the combination IRI + 5-FU regime and IRI
monotherapy arms (Figure 5) (HR 0.91, with 95% CI of 0.81 to
1.02). No heterogeneity within and between subgroups was ob-
served. Results were downgraded from high to low due to study
limitations (Allocation concealment was only clear for one of the
five studies, open-label intervention) and imprecision (Lack of suf-
ficient number of samples may have reduced the statistical power
of the analysis) (Summary of findings for the main comparison).
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Figure 5. Overall survival.
1.2 Progression-free survival
Three studies provided data on PFS (Clarke 2011; Graeven 2007;
Saltz 2000). An increase in progression-free survival was seen in
the combination IRI + 5-FU arm overall, with a hazard ratio of
0.68 (95% CI: 0. 53-0.87). Overall, no substantial heterogeneity
was found (I2 = 13%), and the difference between subgroups failed
to reach significance (p=0.13). Nevertheless, results may have been
largely driven by the study with first-line setting (Saltz 2000), and
the summary HR for second-line treatments showed no difference
in risk of disease progression between the experimental and con-
trol group (Figure 6). This finding was downgraded from high to
moderate due to study limitations (Allocation concealment was
only clear for one of the five studies, open-label intervention)
(Summary of findings for the main comparison).
Figure 6. Progression-free survival
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2. Secondary outcomes
2.1 Response to treatment
Response rates to treatment in the two arms were compared, which
included CR and PR as the outcome of interest. No difference
was observed with all studies combined. Individually or second-
line treatments by themselves (Figure 7), first-line treatment with
the combination IRI + 5-FU chemotherapy were shown to result
in higher response rates (RR for CR and PR: 2.18 (95% CI: 1.50-
3.02)) compared to the controls. However, there was substantial
heterogeneity overall (I2 > 50%). We therefore performed a sen-
sitivity analysis in which we excluded a study with an additional
chemotherapeutic agent in both arms (Bécouarn 2001), which
may have introduced bias. Re-running the random effects model
with this study excluded eliminated the overall heterogeneity and
yielded a summary RR of 1.77 (95% CI: 1.32-2.39; results not
shown in figures), indicating better responses to treatment in the
intervention arm compared to controls.
Figure 7. Response to treatment (CR + PR)
2.2 Toxicity
Toxicity profiles were reported in both first- and second-line treat-
ments and combined, where information on individual toxicities
was available. For grade 3/4 diarrhoea, a reduced overall risk was
observed in the combination IRI + 5-FU arm (RR: 0.66 (95%
CI: 0.48-0.91) compared to the controls (Figure 8). A similar risk
reduction was seen for grade 1/2 alopecia (RR: 0.45 (95% CI:
0.28-0.74), while an increased risk of grade 3/4 neutropenia was
observed in the experimental group (RR: 1.98 (95% CI: 1.48-
2.67) compared to the IRI arm. No marked difference was seen
for other toxicities including grade 3 or 4 mucositis, nausea, and
vomiting, and neuropathy (Figure 9; Figure 10; Figure 11; Figure
12; Figure 13; Figure 14; Figure 15). For grade 1 or 2 alopecia and
neuropathy, only estimates from 2 studies were available. How-
ever, a decision to pool the results was made based on similar treat-
ment arms. No marked heterogeneity was found unless for anal-
ysis of grade 3 or 4 neutropenia (I2: 48%). A sensitivity analysis
for grade 3 or 4 neutropenia excluding a study by Bécouarn 2001,
which included oxaliplatin in both treatment arms, revealed less
heterogeneity without altering the findings (RR: 1.79 (95% CI:
1.49-2.28); I2: 28%, results not shown in figures). Summary of
findings table 2showed downgrading of evidence for toxicity out-
comes grade 3/4 diarrhea to moderate due to study limitation, and
grade 3/4 nausea to low due to study limitations and imprecision.
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Figure 8. Grade 3/4 diarrhea
Figure 9. Grade 3/4 mucositis
Figure 10. Grade 3/4 nausea
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Figure 11. Grade 3/4 vomiting
Figure 12. Grade 3/4 neutropenia
Figure 13. Febrile neutropenia
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Figure 14. Grade 1/2 alopecia
Figure 15. Neuropathy
2.3 Quality of life
Quality of life was assessed in three studies (Clarke 2011; Saltz
2000; Seymour 2007). However, no detailed results were reported
to enable a meta-analysis. Findings varied for comparisons of over-
all quality of life between the experimental and control arms. Saltz
2000 reported higher global health status for the combination IRI
and 5-FU regimen, although these results were not statistically
significant. On the contrary, Clarke 2011 showed a statistically
significant lower overall quality of life with the combination che-
motherapy. No benefit or disadvantage was observed between the
two groups in Seymour 2007.
D I S C U S S I O N
Summary of main results
Five studies fulfilled the inclusion criteria and were included in this
review. High risk of bias due to the lack of blinding was seen with
the Saltz 2000 study. Low risk of selection bias based on allocation
concealment was shown in one study (Clarke 2011), whereas low
risk based on randomisation techniques was seen in two studies
(Clarke 2011; Seymour 2007). There was a lack of sufficient in-
formation to fully assess other sources of bias. Overall, no OS ben-
efit was seen by combining IRI with fluoropyrimidine for treating
advanced or metastatic CRC compared to using IRI alone. Longer
PFS and higher response rates were seen in the combination IRI
+ 5-FU arms. However, these results may have been driven by the
single first-line treatment study, and for treatment response rates
there was substantial heterogeneity. Toxicity profiles were differ-
ent, with higher risks of grade 3 or 4 diarrhoea and grade 1 or 2
alopecia and a lower risk of grade 3 or 4 neutropenia in the control
group compared to the combination arm. No conclusive results
were available for quality of life.
Overall completeness and applicability of
evidence
Overall, our findings indicate no clinical advantage of the com-
bination of IRI and fluoropyrimidine treatment over IRI alone
for patients with advanced or metastatic CRC, but our results
were limited by the number of studies available for each treatment
line. The significant heterogeneity between first- and second- line
groups indicate that results may only be interpreted with respect
to treatment settings.
Quality of the evidence
The quality of evidence in this review was classified as low and
moderate (Summary of findings for the main comparison). This
20Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in
patients with advanced and/or metastatic colorectal cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
was mostly due to high risk of bias assessed through the meta-
analysis and imprecision of results due to a lack of statistical power.
When substantial heterogeneity was found such as in the assess-
ment of response rates, lthough it was likely that the line of treat-
ment is the major determinant of this heterogeneity, the plausi-
ble mechanism underlying the different effects on survival with
respect to treatment setting is unclear. It is possible that treat-
ment setting is a proxy of other prognostic factors in advanced
or metastatic CRC, and therefore the observed heterogeneity re-
flects the difference in population characteristics rather than the
interventions. Additionally, the small numbers of participants and
a lack of studies with first-line settings as mentioned above may
indicate the necessity of confirming our findings through larger
clinical studies sufficiently addressing each line of treatment.
Potential biases in the review process
The inclusion of randomised studies comprising first- and second-
line treatments strengthened this current review. However, even
though similar drugs and routes of administration were used in all
the included studies, there was variation in dosage and timings that
may have affected the overall findings. Nevertheless, several studies
suggested similar efficacy in treating advanced and metastatic CRC
across IRI-based regimens with different intervals of IRI adminis-
tration (Aranda 2009; Bouzid 2003), although further investiga-
tions are needed to delineate the impact of administration routes
and other agents in combination with IRI. Additionally, only 5-
FU-based regimens represented the fluoropyrimidine arm in this
review. As differences in clinical outcomes have been reported with
different fluoropyrimidine agents in IRI-based regimens (Fuchs
2007), this may limit the generalisability of our findings.
In the study conducted by Seymour and colleagues (Seymour
2007), a sequential strategy was employed in which allocation to
both first- and second-line chemotherapy was performed at the
start of the study. Patient eligibility was assessed prior to first-line
of treatment and this may have explained the high proportions of
patients who did not receive the allocated second-line treatments
after failure in the first-line setting. Insufficient patients may also
have limited the results of this review, since a number of analyses
had hazard ratios with wide CI. However, this is not likely the
case for OS since a consistency between subgroups with first- and
second-line treatments was observed. For PFS and response rates,
the benefit in the combination group was affected by inclusion of
the first-line treatment setting study (Saltz 2000). Since marked
heterogeneity between subgroups was found, this signified the im-
portance of conducting subgroup analyses based on first- or sec-
ond-line treatments. Such individualised interpretation may also
be more useful when translating these findings to clinical con-
text. Through the sensitivity analyses, we observed that including
studies with an additional agent in both arms (oxaliplatin in this
case) (Bécouarn 2001) increased heterogeneity in the final anal-
yses. The different associations observed in presence of common
additional agents, i.e. oxaliplatin, suggest that great care should be
made when designing studies and choosing statistical methods to
compare IRI with and without fluoropyrimidine where additional
chemotherapeutic or biological agents are used. Finally, the fact
that one ongoing study from the additional search have not yet
been incorporated may be a source of potential bias.
Agreements and disagreements with other
studies or reviews
A similar review was published in 2011, focusing on the use of IRI
and 5-FU compared to IRI alone as a second-line treatment for
advanced or metastatic CRC (Clarke 2011), which included three
studies that were also selected here (Clarke 2011; Graeven 2007;
Seymour 2007). In this previous review, there was no significant
benefit or disadvantage in OS or PFS by adding 5-FU to IRI, which
was similar to what we found for the second-line treatment setting.
In the current review, comparisons of toxicities were performed
only for studies providing toxicity profiles of both experimental
and control arms in both first- and second-line treatments instead
of combining results from single-arm trials. Interestingly, for grade
3 or 4 diarrhea and grade 1 or 2 alopecia, the findings presented
here were similar to that obtained from the single-arm studies in
Clarke 2011, with higher risks observed in the single IRI arm. We
also observed an increased risk of grade 3 or 4 neutropenia in the
experimental arm. This may occur because neutropenia is a well-
known adverse effect of both IRI and 5-FU. o Nevertheless, no
difference in febrile neutropenia was observed between treatment
arms.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Given available data from clinical trials and large heterogeneity in
reported findings, there is no evidence to suggest any superiority
in OS of the combination of IRI and fluoropyrimidine over IRI
alone. Patients in the combination arm were shown to have longer
PFS, but the moderate quality of the evidence indicates the neces-
sity to confirm findings from this review in clinical studies with
adequate sample size to address potential subgroup effects. Risks
of grade 3 or 4 diarrhea and grade 1 or 2 alopecia were higher in
the intervention arm compared to in controls, whereas the risk of
grade 3 or 4 neutropenia was higher in the control group. These
different toxicity profiles indicate the need for further considera-
tion when selecting a suitable treatment based on individual char-
acteristics of the patients at baseline.
Implications for research
Despite the emergence of targeted therapies, IRI and fluoropyrim-
idine remain an important components of the regimens used in
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treating advanced and metastatic CRC. Therefore, more clinical
trials with sufficient numbers of patients in each line of treatment
are needed to confirm any benefit seen with regimens containing
the combination of IRI and fluoropyrimidine for CRC treatment
compared to those containing IRI alone. It would be of interest
for trialists to assess both regimens in combination with more re-
cent biological agents, and include other administration routes,
in order to achieve optimal clinical benefits. The ongoing study
in ‘Studies awaiting classification’ may alter the conclusions of the
review once results are available and incorporated.This also calls
for designs of RCT protocols that allow for an unbiased compar-
ison between groups of patients receiving IRI with and without
the addition of fluoropyrimidine.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bécouarn 2001
Methods Randomized controlled trial
Phase II, multicenter
Participants CRC with progressive disease after no more than one regimen of optimal 5-FU FA-based
chemotherapy for metastatic disease and/or no more than one line of 5-FU-containing
treatment after prior adjuvant chemotherapy if discontinued less than 6 months




Notes Oxaliplatin IV was administered in both treatment arms
IR + oxaliplatin had longer survivals and better toxicity profile
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No mention of how randomization se-
quence was generated
Allocation concealment (selection bias) Unclear risk No mention of any allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding of participants and
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding of outcome assess-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two patients in the control arm did not
received any treatment due to a move to a
nonparticipating study site in one case and
worsening of general status in the other.
However they were included in the analysis
Selective reporting (reporting bias) Unclear risk No reported pre-specified outcomes
Other bias Low risk None
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Clarke 2011
Methods Randomized controlled trial
Phase II, multicenter
Participants Incurable locally advanced or metastatic
CRC, progressive disease after one prior chemotherapy regimen for advanced disease
and/or after prior adjuvant therapy, provided that relapse had occurred within 6 months
of that treatment




Notes Trial was terminated due to slow recruitment.
Similar efficacy between the two arms but IRI + 5-FU/LV had slightly less toxicities
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Minimisation
Allocation concealment (selection bias) Low risk Central randomization/allocation by tele-
phone
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding of participants and
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding of outcome assess-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Four patients withdrew early (2 in the in-
tervention and 2 in the control arm). Three
withdrew before baseline tumour assess-
ment and did not receive any treatment.
The fourth one opted 3 days after consent
to receive off-study irinotecan and cetux-
imab. These patients were included in the
analysis, except one who explicitly refused
Selective reporting (reporting bias) Unclear risk No reported pre-specified outcomes
Other bias Low risk None
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Graeven 2007
Methods Randomized controlled trial
Phase II, multicenter
Participants Metastatic CRC after failure of a first-line chemotherapy, pretreatment was to consist
of either 5-FU/LV, capecitabine or 5-FU/LV in combination with oxaliplatin, whereas
irinotecan-containing regimens were not allowed




Notes No marked difference was observed between the two groups.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No mention of how randomization se-
quence was generated
Allocation concealment (selection bias) Unclear risk No mention of any allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding of participants and
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding of outcome assess-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Two patients were withdrawn prior to the
first administration, but reasons for this
were not reported and there was no men-
tion of which treatment arm they were ran-
domized to. Both patients were not in-
cluded in the analysis
Selective reporting (reporting bias) Unclear risk No reported pre-specified outcomes
Other bias Low risk None
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Saltz 2000
Methods Randomized controlled trial
Phase III, multicenter
Participants Metastatic CRC, no prior therapy for metastatic disease; patients who had received
adjuvant 5-FU-based therapy were eligible if they had remained free of disease for at
least one year after the completion of adjuvant therapy




Notes The study had another treatment arm with 5-FU/LV alone. IRI + 5-FU/LV was superior
to FU/LV alone but not directly compared with IRI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No mention of how randomization se-
quence was generated
Allocation concealment (selection bias) Unclear risk No mention of any allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label, thus no blinding of partici-
pants and personnel was performed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding of outcome assess-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Six patients in the intervention group and
three patients in the control arm either did
not receive any treatment or received the
wrong treatment. However, they were in-
cluded in the analysis
Selective reporting (reporting bias) Unclear risk No reported pre-specified outcomes
Other bias Low risk None
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Seymour 2007
Methods Randomized controlled trial
Participants Inoperable metastatic or locoregional CRC




Notes The intervention arms were part of sequential treatments with three strategies. Two
among these administered 5-FU as the first-line treatment, followed by a second-line
treatment with IRI in the control group and either IRI + 5-FU or oxaliplatin in the
intervention group. The third strategy used the combination of IRI or oxaliplatin with
5-FU as the first-line treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Minimisation
Allocation concealment (selection bias) Unclear risk No mention of any allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding of participants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Among 339 patients in the intervention group who failed
first-line treatment, 110 died or progressed to terminal
care prior to administration and 44 received alternative
second-line regimen. Among 666 patients in the control
group who failed first-line treatment, 251 died or pro-
gressed to terminal care prior to administration and 51
received alternative second-line regimen. However, these
patients were included in the analysis
Selective reporting (reporting bias) Unclear risk No reported pre-specified outcomes
Other bias Low risk None
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Fiorentini 2012 IRI was not administered via an IV or oral route
Mitchell 2011 Assignments to IRI or IRI + 5-FU were not randomized
Popov 2006 Assignments to IRI or IRI + 5-FU were not randomized
Characteristics of studies awaiting assessment [ordered by study ID]
Bendell 2014
Methods Open label RCT / three arm study
Participants 280 adult patients (both gender), aged 18-75, with a histologically confirmed colorectal cancer with at least on
measurable metastatic lesion
Interventions Exp A - FOLFOXFIRI + Bevacizumab; Exp B - sequential FOLFOXFIRI + Bevacizumab; Exp C - FOLFOX +
Bevacizumab
Outcomes Primary - Overall response rate (ORR1); and progression-free survival (PFS1) during first line therapy
Secondary - Overall response rate during second line therapy (ORR2); progression-free survival during second line
therapy (PFS2); Time to PFS2; Overall survival (OS); Liver resection rate; Rates of conversion from unresectable to
resectable disease; Adverse events
Notes The study is ongoing but not recruiting. Estimated primary completion December 2016
30Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in
patients with advanced and/or metastatic colorectal cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Overall Survival




participants Statistical method Effect size
1 Overall survival 5 1728 Hazard Ratio (Random, 95% CI) 0.91 [0.81, 1.02]
1.1 First-line treatments 1 457 Hazard Ratio (Random, 95% CI) 0.88 [0.69, 1.12]
1.2 Second-line treatments 4 1271 Hazard Ratio (Random, 95% CI) 0.92 [0.75, 1.14]
2 Overall survival 5 1728 Hazard Ratio (95% CI) 0.88 [0.75, 1.05]
Comparison 2. Progression-Free Survival




participants Statistical method Effect size
1 Progression-free survival 3 600 Hazard Ratio (Random, 95% CI) 0.68 [0.53, 0.87]
1.1 First-line treatments 1 457 Hazard Ratio (Random, 95% CI) 0.59 [0.45, 0.77]
1.2 Second-line treatments 2 143 Hazard Ratio (Random, 95% CI) 0.83 [0.58, 1.19]
Comparison 3. Response to Treatment




participants Statistical method Effect size
1 Objective response (CR + PR) 5 1199 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.80, 2.24]
1.1 First-line treatments 1 448 Risk Ratio (M-H, Random, 95% CI) 2.18 [1.58, 3.02]
1.2 Second-line treatments 4 751 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.50, 1.96]
Comparison 4. Toxicity




participants Statistical method Effect size
1 Grade 3/4 diarrhea 5 1179 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.48, 0.91]
2 Grade 3/4 mucositis 4 1117 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.45, 3.11]
3 Grade 3/4 nausea 3 209 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.07, 1.58]
4 Grade 3/4 vomiting 4 650 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.47, 1.24]
5 Grade 3/4 neutropenia 5 1179 Risk Ratio (M-H, Random, 95% CI) 1.79 [1.29, 2.48]
6 Febrile neutropenia 3 595 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.53, 2.78]
7 Grade 1/2 alopecia 2 140 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.28, 0.74]
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8 Neuropathy 2 591 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.27, 5.42]
9 Grade 3/4 anemia 2 117 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.08, 5.19]
Analysis 1.1. Comparison 1 Overall Survival, Outcome 1 Overall survival.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 1 Overall Survival
Outcome: 1 Overall survival
Study or subgroup IRI + 5-FU IRI log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 First-line treatments
Saltz 2000 231 226 -0.1278 (0.1241) 22.5 % 0.88 [ 0.69, 1.12 ]
Subtotal (95% CI) 231 226 22.5 % 0.88 [ 0.69, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
2 Second-line treatments
B couarn 2001 32 30 0.5008 (0.5077) 1.3 % 1.65 [ 0.61, 4.46 ]
Clarke 2011 44 44 -0.3285 (0.2286) 6.6 % 0.72 [ 0.46, 1.13 ]
Graeven 2007 28 27 0.27 (0.3345) 3.1 % 1.31 [ 0.68, 2.52 ]
Seymour 2007 356 710 -0.0943 (0.0722) 66.4 % 0.91 [ 0.79, 1.05 ]
Subtotal (95% CI) 460 811 77.5 % 0.92 [ 0.75, 1.14 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.60, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 691 1037 100.0 % 0.91 [ 0.81, 1.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.68, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.096)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
0.2 0.5 1 2 5
Favours IRI + 5-FU Favours IRI
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Analysis 1.2. Comparison 1 Overall Survival, Outcome 2 Overall survival.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 1 Overall Survival
Outcome: 2 Overall survival








Clarke 2011 18/44 26/44 5.7 % 0.67 [ 0.33, 1.36 ]
Saltz 2000 102/231 116/226 29.3 % 0.84 [ 0.61, 1.14 ]
Seymour 2007 149/356 313/710 58.1 % 0.89 [ 0.71, 1.11 ]
Graeven 2007 21/28 20/27 4.0 % 1.13 [ 0.48, 2.64 ]
B couarn 2001 19/32 14/30 2.9 % 1.65 [ 0.61, 4.45 ]
Total (95% CI) 100.0 % 0.88 [ 0.75, 1.05 ]
Heterogeneity: Chi2 = 2.57, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours IRI + 5-FU Favours IRI
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Analysis 2.1. Comparison 2 Progression-Free Survival, Outcome 1 Progression-free survival.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 2 Progression-Free Survival
Outcome: 1 Progression-free survival
Study or subgroup IRI + 5-FU IRI log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 First-line treatments
Saltz 2000 231 226 -0.5276 (0.1382) 58.6 % 0.59 [ 0.45, 0.77 ]
Subtotal (95% CI) 231 226 58.6 % 0.59 [ 0.45, 0.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.82 (P = 0.00013)
2 Second-line treatments
Clarke 2011 44 44 -0.2107 (0.2261) 26.1 % 0.81 [ 0.52, 1.26 ]
Graeven 2007 28 27 -0.1393 (0.3034) 15.3 % 0.87 [ 0.48, 1.58 ]
Subtotal (95% CI) 72 71 41.4 % 0.83 [ 0.58, 1.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 303 297 100.0 % 0.68 [ 0.53, 0.87 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.29, df = 2 (P = 0.32); I2 =13%
Test for overall effect: Z = 3.14 (P = 0.0017)
Test for subgroup differences: Chi2 = 2.26, df = 1 (P = 0.13), I2 =56%
0.2 0.5 1 2 5
Favours IRI + 5-FU Favours IRI
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Analysis 3.1. Comparison 3 Response to Treatment, Outcome 1 Objective response (CR + PR).
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 3 Response to Treatment
Outcome: 1 Objective response (CR + PR)









Saltz 2000 88/225 40/223 36.0 % 2.18 [ 1.58, 3.02 ]
Subtotal (95% CI) 225 223 36.0 % 2.18 [ 1.58, 3.02 ]
Total events: 88 (IRI + 5-FU), 40 (IRI)
Heterogeneity: not applicable
Test for overall effect: Z = 4.71 (P < 0.00001)
2 Second-line treatments
B couarn 2001 2/32 7/30 9.3 % 0.27 [ 0.06, 1.19 ]
Graeven 2007 3/28 3/27 9.1 % 0.96 [ 0.21, 4.37 ]
Clarke 2011 5/42 5/43 13.4 % 1.02 [ 0.32, 3.28 ]
Seymour 2007 30/185 39/364 32.1 % 1.51 [ 0.97, 2.35 ]
Subtotal (95% CI) 287 464 64.0 % 0.99 [ 0.50, 1.96 ]
Total events: 40 (IRI + 5-FU), 54 (IRI)
Heterogeneity: Tau2 = 0.20; Chi2 = 5.11, df = 3 (P = 0.16); I2 =41%
Test for overall effect: Z = 0.02 (P = 0.99)
Total (95% CI) 512 687 100.0 % 1.34 [ 0.80, 2.24 ]
Total events: 128 (IRI + 5-FU), 94 (IRI)
Heterogeneity: Tau2 = 0.17; Chi2 = 9.73, df = 4 (P = 0.05); I2 =59%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Chi2 = 4.18, df = 1 (P = 0.04), I2 =76%
0.01 0.1 1 10 100
Favours IRI Favours IRI + 5-FU
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Analysis 4.1. Comparison 4 Toxicity, Outcome 1 Grade 3/4 diarrhea.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 4 Toxicity
Outcome: 1 Grade 3/4 diarrhea








B couarn 2001 6/32 3/30 5.7 % 1.88 [ 0.51, 6.83 ]
Clarke 2011 4/42 8/43 7.5 % 0.51 [ 0.17, 1.57 ]
Graeven 2007 3/28 5/27 5.4 % 0.58 [ 0.15, 2.19 ]
Saltz 2000 51/225 69/223 55.8 % 0.73 [ 0.54, 1.00 ]
Seymour 2007 14/180 58/349 25.6 % 0.47 [ 0.27, 0.82 ]
Total (95% CI) 507 672 100.0 % 0.66 [ 0.48, 0.91 ]
Total events: 78 (IRI + 5-FU), 143 (IRI)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.66, df = 4 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.55 (P = 0.011)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Toxicity, Outcome 2 Grade 3/4 mucositis.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 4 Toxicity
Outcome: 2 Grade 3/4 mucositis








Clarke 2011 1/42 0/43 9.2 % 3.07 [ 0.13, 73.30 ]
Graeven 2007 0/28 0/27 Not estimable
Saltz 2000 5/225 5/223 61.6 % 0.99 [ 0.29, 3.38 ]
Seymour 2007 2/180 3/349 29.2 % 1.29 [ 0.22, 7.67 ]
Total (95% CI) 475 642 100.0 % 1.19 [ 0.45, 3.11 ]
Total events: 8 (IRI + 5-FU), 8 (IRI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Toxicity, Outcome 3 Grade 3/4 nausea.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 4 Toxicity
Outcome: 3 Grade 3/4 nausea








B couarn 2001 0/32 1/30 24.8 % 0.31 [ 0.01, 7.40 ]
Clarke 2011 1/42 3/43 50.3 % 0.34 [ 0.04, 3.15 ]
Graeven 2007 0/32 1/30 24.8 % 0.31 [ 0.01, 7.40 ]
Total (95% CI) 106 103 100.0 % 0.33 [ 0.07, 1.58 ]
Total events: 1 (IRI + 5-FU), 5 (IRI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Toxicity, Outcome 4 Grade 3/4 vomiting.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 4 Toxicity
Outcome: 4 Grade 3/4 vomiting








B couarn 2001 2/32 4/30 8.8 % 0.47 [ 0.09, 2.37 ]
Clarke 2011 2/42 2/43 6.4 % 1.02 [ 0.15, 6.94 ]
Graeven 2007 0/28 1/27 2.3 % 0.32 [ 0.01, 7.57 ]
Saltz 2000 22/225 27/223 82.5 % 0.81 [ 0.47, 1.37 ]
Total (95% CI) 327 323 100.0 % 0.76 [ 0.47, 1.24 ]
Total events: 26 (IRI + 5-FU), 34 (IRI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Toxicity, Outcome 5 Grade 3/4 neutropenia.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 4 Toxicity
Outcome: 5 Grade 3/4 neutropenia








B couarn 2001 17/32 14/30 23.1 % 1.14 [ 0.69, 1.88 ]
Clarke 2011 6/42 2/43 4.2 % 3.07 [ 0.66, 14.37 ]
Graeven 2007 7/28 0/27 1.3 % 14.48 [ 0.87, 241.82 ]
Saltz 2000 121/225 70/223 40.4 % 1.71 [ 1.36, 2.15 ]
Seymour 2007 50/180 43/349 31.0 % 2.25 [ 1.56, 3.25 ]
Total (95% CI) 507 672 100.0 % 1.79 [ 1.29, 2.48 ]
Total events: 201 (IRI + 5-FU), 129 (IRI)
Heterogeneity: Tau2 = 0.06; Chi2 = 7.65, df = 4 (P = 0.11); I2 =48%
Test for overall effect: Z = 3.47 (P = 0.00052)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Toxicity, Outcome 6 Febrile neutropenia.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 4 Toxicity
Outcome: 6 Febrile neutropenia








B couarn 2001 4/32 1/30 13.9 % 3.75 [ 0.44, 31.68 ]
Clarke 2011 1/42 3/43 12.9 % 0.34 [ 0.04, 3.15 ]
Saltz 2000 16/225 13/223 73.3 % 1.22 [ 0.60, 2.48 ]
Total (95% CI) 299 296 100.0 % 1.21 [ 0.53, 2.78 ]
Total events: 21 (IRI + 5-FU), 17 (IRI)
Heterogeneity: Tau2 = 0.12; Chi2 = 2.33, df = 2 (P = 0.31); I2 =14%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Toxicity, Outcome 7 Grade 1/2 alopecia.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 4 Toxicity
Outcome: 7 Grade 1/2 alopecia








Clarke 2011 6/43 16/42 34.8 % 0.37 [ 0.16, 0.85 ]
Graeven 2007 9/28 17/27 65.2 % 0.51 [ 0.28, 0.94 ]
Total (95% CI) 71 69 100.0 % 0.45 [ 0.28, 0.74 ]
Total events: 15 (IRI + 5-FU), 33 (IRI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.13 (P = 0.0017)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Toxicity, Outcome 8 Neuropathy.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 4 Toxicity
Outcome: 8 Neuropathy








B couarn 2001 1/30 1/32 29.9 % 1.07 [ 0.07, 16.30 ]
Seymour 2007 2/180 3/349 70.1 % 1.29 [ 0.22, 7.67 ]
Total (95% CI) 210 381 100.0 % 1.22 [ 0.27, 5.42 ]
Total events: 3 (IRI + 5-FU), 4 (IRI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Toxicity, Outcome 9 Grade 3/4 anemia.
Review: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced
and/or metastatic colorectal cancer
Comparison: 4 Toxicity
Outcome: 9 Grade 3/4 anemia








B couarn 2001 1/30 1/32 57.3 % 1.07 [ 0.07, 16.30 ]
Graeven 2007 0/27 1/28 42.7 % 0.35 [ 0.01, 8.12 ]
Total (95% CI) 57 60 100.0 % 0.66 [ 0.08, 5.19 ]
Total events: 1 (IRI + 5-FU), 2 (IRI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IRI + 5-FU Favours IRI
A D D I T I O N A L T A B L E S
Table 1. Characteristics of studies
Study Group Chemotherapy agent
(s)
Additional agent(s) Cycle interval Median overall survival
(months)
Bécouarn 2001 Intervention IRI 180 mg/m2 IV 90
min on Day 1
5-FU 400 mg/m2 IV
bolus and 600 mg/m2
IV 22 hrs on Day 1,2,
15,16
Oxaliplatin on Day 1 4 weeks 9.8 (6.4-13)
Control IRI 200 mg/m2 IV 30
min on Day 1
Oxaliplatin on Day 15 3 weeks 12.3 (9.8-14.8)
Clarke 2011 Intervention IRI 180 mg/m2 IV 90
min on Day 1
5-FU 400 mg/m2 IV
bolus and 2400 mg/
m2 IV 46 hrs on Day 1
2 weeks 15.4 (8.1-18)
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Table 1. Characteristics of studies (Continued)
Control IRI 300-350 mg/m2
IV 90 min on Day 1
3 weeks 11.2 (8.3-13.3)
Graeven 2007 Intervention IRI 80 mg/m2 IV 60
min on Day 1,8,15,22,
29,36
5-FU 2000 mg/m2 IV
24 hrs on Day 1,8,15,
22,29,36
7 weeks 9.5 (6.5-13)
Control IRI 125 mg/m2 IV 30-
60 min on Day 1,8,15,
22
6 weeks 10.7 (8-12.9)
Saltz 2000 Intervention IRI 125 mg/m2 IV 90
min on Day 1,8,15,22
5-FU 500 mg/m2 IV
bolus on Day 1,8,15,
22 and 5-FU 425 mg/
m2 IV bolus on Day 1-
5
6 weeks 14.8
Control IRI 125 mg/m2 IV 90
min on Day 1,8,15,22
6 weeks 12
Seymour 2007 Intervention IRI 180 mg/m2 IV 30
min on Day 1
5-FU 400 mg/m2 IV
bolus and 2400 mg/
m2 IV 46 hrs on Day 1
2 weeks 15
Control IRI 350 mg/m2 IV 30-
90 min on Day 1
3 weeks 13.9
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Colorectal Neoplasms] explode all trees
#2 ((colorect* or colon or colonic or rect* or anal* or anus* or intestin* or bowel*) near/3 (carcinom* or neoplas* or adenocarcinom*
or cancer* or tumor* or tumour* or sarcom* or metastas*)):ti,ab,kw
#3 (#1 or #2)
#4 MeSH descriptor: [Camptothecin] explode all trees
#5 (irinotecan* or camptothecin* or biotecan or Camptosar or camptothecin-11 or CPT-11 or SN-38):ti,ab,kw
#6 (#4 or #5)
#7 (#3 and #6)
Appendix 2. MEDLINE search strategy
1. *Colorectal Neoplasms/
2. ((colorect* or colon or colonic or rect* or anal* or anus* or intestin* or bowel*) and (carcinom* or neoplas* or adenocarcinom* or
cancer* or tumor* or tumour* or sarcom* or metastas*)).m˙titl.
3. 1 or 2
4. exp Camptothecin/
5. (irinotecan* or camptothecin* or biotecan or Camptosar or camptothecin-11 or CPT-11 or SN-38).m˙titl.
6. 4 or 5
7. 3 and 6
8. randomized controlled trial.pt.
9. controlled clinical trial.pt.
10. randomized.ab.
11. placebo.ab.
12. clinical trial as topic.sh.
13. randomly.ab.
14. trial.ti.
15. 8 or 9 or 10 or 11 or 12 or 13 or 14
16. Exp animals/ not humans.sh.
17. 15 not 16
18. 7 and 17
Appendix 3. EMBASE search strategy
1. *colorectal cancer/
2. ((colorect* or colon or colonic or rect* or anal* or anus* or intestin* or bowel*) and (carcinom* or neoplas* or adenocarcinom* or
cancer* or tumor* or tumour* or sarcom* or metastas*)).m˙titl.
3. 1 or 2
4. *irinotecan/
5. (irinotecan* or camptothecin* or biotecan or Camptosar or camptothecin-11 or CPT-11 or SN-38).m˙titl.
6. 4 or 5




11. (crossover* or cross over*).ti,ab.
12. placebo*.ti,ab.
13. (doubl* adj blind*).ti,ab.
14. allocat*.ti,ab.
15. trial.ti.
16. RANDOMIZED CONTROLLED TRIAL.sh.
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17. random*.ti,ab.
18. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. (exp animal/ or exp invertebrate/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans or man or
men or wom?n).ti.)
20. 18 not 19
21. 7 and 20
Appendix 4. Science Citation Index search strategy
#1 Title: ((colorect* or colon or colonic or rect* or anal* or anus* or intestin* or bowel*) near/3 (carcinom* or neoplas* or adenocarcinom*
or cancer* or tumor* or tumour* or sarcom* or metastas*))
#2 Title: (irinotecan* or camptothecin* or biotecan or Camptosar or camptothecin-11 or CPT-11 or SN-38)
#3 TOPIC: (controlled trial or controlled clinical trial or placebo or clinical trial or random* or trial or cct or rct)
#4 (#3 AND #2 AND #1)
Appendix 5. Criteria for judging risk of bias in the ’Risk of bias’ assessment tool
RANDOM SEQUENCE GENERATION
Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence
Criteria for a judgement of ‘Low risk’ of bias. The investigators describe a random component in the sequence
generation process such as:
· Referring to a random number table;
· Using a computer random number generator;
· Coin tossing;
· Shuffling cards or envelopes;
· Throwing dice;
· Drawing of lots;
· Minimization*.
*Minimization may be implemented without a random element,
and this is considered to be equivalent to being random
Criteria for the judgement of ‘High risk’ of bias. The investigators describe a non-random component in the se-
quence generation process. Usually, the description would involve
some systematic, non-random approach, for example:
· Sequence generated by odd or even date of birth;
· Sequence generated by some rule based on date (or day) of ad-
mission;
· Sequence generated by some rule based on hospital or clinic
record number
· Other non-random approaches happen much less frequently
than the systematic approaches mentioned above and tend to be
obvious. They usually involve judgement or some method of non-
random categorization of participants, for example:
· Allocation by judgement of the clinician;
· Allocation by preference of the participant;
· Allocation based on the results of a laboratory test or a series of
tests;
· Allocation by availability of the intervention.
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(Continued)
Criteria for the judgement of ‘Unclear risk’ of bias. Insufficient information about the sequence generation process to
permit judgement of ‘Low risk’ or ‘High risk’
ALLOCATION CONCEALMENT
Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment
Criteria for a judgement of ‘Low risk’ of bias. Participants and investigators enrolling participants could not
foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation:
· Central allocation (including telephone, web-based and phar-
macy-controlled randomization);
· Sequentially numbered drug containers of identical appearance;
· Sequentially numbered, opaque, sealed envelopes.
Criteria for the judgement of ‘High risk’ of bias. Participants or investigators enrolling participants could possibly
foresee assignments and thus introduce selection bias, such as al-
location based on:
· Using an open random allocation schedule (e.g. a list of random
numbers);
· Assignment envelopes were used without appropriate safeguards
(e.g. if envelopes were unsealed or nonopaque or not sequentially
numbered);
· Alternation or rotation;
· Date of birth;
· Case record number;
· Any other explicitly unconcealed procedure.
Criteria for the judgement of ‘Unclear risk’ of bias. Insufficient information to permit judgement of ‘Low risk’ or
‘High risk’. This is usually the case if the method of concealment
is not described or not described in sufficient detail to allow a def-
inite judgement - for example if the use of assignment envelopes is
described, but it remains unclear whether envelopes were sequen-
tially numbered, opaque and sealed
BLINDING OF PARTICIPANTS AND PERSONNEL
Performance bias due to knowledge of the allocated interventions by participants and personnel during the study
Criteria for a judgement of ‘Low risk’ of bias. Any one of the following:
· No blinding or incomplete blinding, but the review authors
judge that the outcome is not likely to be influenced by lack of
blinding;
· Blinding of participants and key study personnel ensured, and
unlikely that the blinding could have been broken
Criteria for the judgement of ‘High risk’ of bias. Any one of the following:
· No blinding or incomplete blinding, and the outcome is likely
to be influenced by lack of blinding;
· Blinding of key study participants and personnel attempted, but
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(Continued)
likely that the blinding could have been broken, and the outcome
is likely to be influenced by lack of blinding
Criteria for the judgement of ‘Unclear risk’ of bias. Any one of the following:
· Insufficient information to permit judgement of ‘Low risk’ or
‘High risk’;
· The study did not address this outcome.
BLINDING OF OUTCOME ASSESSMENT
Detection bias due to knowledge of the allocated interventions by outcome assessors
Criteria for a judgement of ‘Low risk’ of bias. Any one of the following:
· No blinding of outcome assessment, but the review authors judge
that the outcome measurement is not likely to be influenced by
lack of blinding;
· Blinding of outcome assessment ensured, and unlikely that the
blinding could have been broken
Criteria for the judgement of ‘High risk’ of bias. Any one of the following:
· No blinding of outcome assessment, and the outcome measure-
ment is likely to be influenced by lack of blinding;
· Blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Criteria for the judgement of ‘Unclear risk’ of bias. Any one of the following:
· Insufficient information to permit judgement of ‘Low risk’ or
‘High risk’;
· The study did not address this outcome.
INCOMPLETE OUTCOME DATA
Attrition bias due to amount, nature or handling of incomplete outcome data
Criteria for a judgement of ‘Low risk’ of bias. Any one of the following:
· No missing outcome data;
· Reasons for missing outcome data unlikely to be related to true
outcome (for survival data, censoring unlikely to be introducing
bias);
· Missing outcome data balanced in numbers across intervention
groups, with similar reasons for missing data across groups;
· For dichotomous outcome data, the proportion of missing out-
comes compared with observed event risk not enough to have a
clinically relevant impact on the intervention effect estimate;
· For continuous outcome data, plausible effect size (difference in
means or standardized difference in means) among missing out-
comes not enough to have a clinically relevant impact on observed
effect size;
· Missing data have been imputed using appropriate methods.
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(Continued)
Criteria for the judgement of ‘High risk’ of bias. Any one of the following:
· Reason for missing outcome data likely to be related to true
outcome, with either imbalance in numbers or reasons for missing
data across intervention groups;
· For dichotomous outcome data, the proportion of missing out-
comes compared with observed event risk enough to induce clin-
ically relevant bias in intervention effect estimate;
· For continuous outcome data, plausible effect size (difference
in means or standardized difference in means) among missing
outcomes enough to induce clinically relevant bias in observed
effect size;
· ‘As-treated’ analysis done with substantial departure of the inter-
vention received from that assigned at randomization;
· Potentially inappropriate application of simple imputation
Criteria for the judgement of ‘Unclear risk’ of bias. Any one of the following:
· Insufficient reporting of attrition/exclusions to permit judge-
ment of ‘Low risk’ or ‘High risk’ (e.g. number randomized not
stated, no reasons for missing data provided);
· The study did not address this outcome.
SELECTIVE REPORTING
Reporting bias due to selective outcome reporting.
Criteria for a judgement of ‘Low risk’ of bias. Any of the following:
· The study protocol is available and all of the study’s pre-specified
(primary and secondary) outcomes that are of interest in the review
have been reported in the pre-specified way;
· The study protocol is not available but it is clear that the pub-
lished reports include all expected outcomes, including those that
were pre-specified (convincing text of this nature may be uncom-
mon)
Criteria for the judgement of ‘High risk’ of bias. Any one of the following:
· Not all of the study’s pre-specified primary outcomes have been
reported;
· One or more primary outcomes is reported using measurements,
analysis methods or subsets of the data (e.g. subscales) that were
not pre-specified;
· One or more reported primary outcomes were not pre-specified
(unless clear justification for their reporting is provided, such as
an unexpected adverse effect);
· One or more outcomes of interest in the review are reported
incompletely so that they cannot be entered in a meta-analysis;
· The study report fails to include results for a key outcome that
would be expected to have been reported for such a study
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(Continued)
Criteria for the judgement of ‘Unclear risk’ of bias. Insufficient information to permit judgement of ‘Low risk’ or
‘High risk’. It is likely that the majority of studies will fall into this
category
OTHER BIAS
Bias due to problems not covered elsewhere in the table.
Criteria for a judgement of ‘Low risk’ of bias. The study appears to be free of other sources of bias.
Criteria for the judgement of ‘High risk’ of bias. There is at least one important risk of bias. For example, the study:
· Had a potential source of bias related to the specific study design
used; or
· Has been claimed to have been fraudulent; or
· Had some other problem.
Criteria for the judgement of ‘Unclear risk’ of bias. There may be a risk of bias, but there is either:
· Insufficient information to assess whether an important risk of
bias exists; or
· Insufficient rationale or evidence that an identified problem will
introduce bias
H I S T O R Y
Protocol first published: Issue 7, 2010
Review first published: Issue 2, 2016
Date Event Description
14 December 2014 New search has been performed New search performed. 945 additional studies found in initial search, but
no new trials identified in full-text search and checked for inclusion
24 June 2013 New search has been performed Updated protocol with new author team
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C O N T R I B U T I O N S O F A U T H O R S
TASKS WHO WILL UNDERTAKE TASKS?
Draft the protocol Wahyu Wulaningsih and Mieke Van Hemelrijck
Develop a search strategy Wahyu Wulaningsih and Mieke Van Hemelrijck
Search for trials Ardyan Wardhana and Naomi Yoshuantari
Select which trials to include Wahyu Wulaningsih and Ardyan Wardhana
Extract data from trials Wahyu Wulaningsih and Naomi Yoshuantari
Enter data into RevMan Wahyu Wulaningsih and Ardyan Wardhana
Carry out the analysis Wahyu Wulaningsih, Ardyan Wardhana, Johnathan Watkins
Interpret the analysis All authors
Draft the final review All authors
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
In the protocol, we specified that only English publications would be included in the review. However, during initial search and selection
of studies, we included trials in all languages and when limiting to studies in English in the latter stage, this made no difference in
studies selected. Therefore, in the current review we no longer limited the studies to publications in English.
The method used to pool estimates from binary outcomes was not specified in the protocol. The use of a Mantel-Haenszel test has
now been included in the review.
In the protocol, we specified that random effects model will be used when heterogeneity is indicated. However, in the review, random
effects model selection was performed for all analyses, and investigations of sources of any results inconsistency by sensitivity analyses
were performed when heterogeneity was indicated.
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